GENERATION HD1 Trial Fails to Show Benefits of Tominersen

GENERATION HD1 Trial Fails to Show Benefits of Tominersen

293722

GENERATION HD1 Trial Fails to Show Benefits of Tominersen

Treatment with tominersen failed to show evidence of clinical benefit in adults with Huntington’s disease during the Phase 3 clinical trial GENERATION HD1. Roche, the company developing tominersen, decided to pause dosing in the clinical trial about a month ago, after a pre-planned review of trial data by an independent data monitoring committee found the treatment did not show a favorable benefits/risk profile. Dosing in GEN-EXTEND (NCT03842969), an open-label extension study for people who participated in…

You must be logged in to read/download the full post.